AnaptysBio Inc ANAB.OQ ANAB.O is expected to show a fall in quarterly revenue when it reports results for the period ending January 1 0001
The San Diego California-based company is expected to report a 7.2% decrease in revenue to $8.353 million from $9.01 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.
LSEG's mean analyst estimate for AnaptysBio Inc is for a loss of $1.59 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 5.6% in the last three months.
Wall Street's median 12-month price target for AnaptysBio Inc is $48.50, above its last closing price of $19.88.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -1.66 | -1.65 | -1.14 | Beat | 30.8 |
Jun. 30 2024 | -0.78 | -0.99 | -1.71 | Missed | -72.9 |
Mar. 31 2024 | -1.56 | -1.57 | -1.64 | Missed | -4.7 |
Dec. 31 2023 | -1.62 | -1.60 | -1.59 | Beat | 0.7 |
Jan. 1 0001 | -1.80 | -1.79 | -1.41 | Beat | 21.4 |
Jun. 30 2023 | -1.83 | -1.70 | -1.50 | Beat | 11.6 |
Jan. 1 0001 | -1.08 | -1.05 | -1.58 | Missed | -50.8 |
Dec. 31 2022 | -0.96 | -0.96 | -0.93 | Beat | 2.8 |
This summary was machine generated November 6 at 14:19 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。